Abivax S.A.

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

3 drugs in development

Phase 31

Phase 22

Phase 11

By Therapeutic Area

top 2

Immunology

133%

Oncology

133%

R&D Momentum

30/100

Pipeline Velocity

6/100

Trial Completion Rate

89/100

Pipeline Concentration

33/100

Pipeline Freshness

64/100

Strategic Signals

↗Active in Immunology but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Sep 11, 2026

Completed

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of ABX464 Once Daily for Induction Treatment in Subjects With Moderately to Severely Active Ulcerative Colitis

Sep 11, 2026

Completed

Earlier

Jul 8, 2026TrialA Randomized, Double-blind, Multicenter Phase III Study to Evaluate the Long-term Efficacy and Safety of ABX464 25 mg or 50 mg Once Daily as a Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis

Mar 1, 2026TrialPhase 1 Study to Evaluate Pharmacokinetics, Relative Bioavailability, Palatability of Obefazimod Minitablet Formulation

Oct 30, 2024TrialEfficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

Sep 19, 2022TrialPhase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease Patients

Dec 3, 2021TrialLong-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis

Sep 27, 2021TrialSafety and Pharmacokinetics Study in Healthy Japanese Volunteers

4 more events

Dec 17, 2020TrialEvaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464

Jul 1, 2020TrialABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19

Jan 13, 2020TrialEfficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis

Oct 25, 2019TrialStudy Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

ABX464Phase 3

Oncology

Hepatocellular Carcinoma

ABX196Phase 2

Unknown / Other

Efficacy and Safety

ObefazimodPhase 2

Phase 1

ObefazimodPhase 1

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)